| PCS-2023 > 3 > 3E > 3E0 > 3E06 |
3E0 | Physiological Systems and Anatomical Regions, Introduction | |
Info: | Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products | |
3E06 | Introduction, Central Artery | |
3E060 | Open | |
3E0600 | Antineoplastic | |
3E06002 | Introduction of High-dose Interleukin-2 into Central Artery, Open Approach | |
3E06003 | Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach | |
3E06005 | Introduction of Other Antineoplastic into Central Artery, Open Approach | |
3E0600M | Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach | |
3E0600P | Introduction of Clofarabine into Central Artery, Open Approach | |
3E0601 | Thrombolytic | |
3E06016 | Introduction of Recombinant Human-activated Protein C into Central Artery, Open | |
3E06017 | Introduction of Other Thrombolytic into Central Artery, Open Approach | |
3E0602 | Anti-infective | |
3E06028 | Introduction of Oxazolidinones into Central Artery, Open Approach | |
3E06029 | Introduction of Other Anti-infective into Central Artery, Open Approach | |
3E0603 | Anti-inflammatory | |
3E0603Z | Introduction of Anti-inflammatory into Central Artery, Open Approach | |
3E0604 | Serum, Toxoid and Vaccine | |
3E0604Z | Introduction of Serum, Toxoid and Vaccine into Central Artery, Open Approach | |
3E0606 | Nutritional Substance | |
3E0606Z | Introduction of Nutritional Substance into Central Artery, Open Approach | |
3E0607 | Electrolytic and Water Balance Substance | |
3E0607Z | Introduction of Electrolytic and Water Balance Substance into Central Artery, Open Approach | |
3E060F | Intracirculatory Anesthetic | |
3E060FZ | Introduction of Intracirculatory Anesthetic into Central Artery, Open Approach | |
3E060H | Radioactive Substance | |
3E060HZ | Introduction of Radioactive Substance into Central Artery, Open Approach | |
3E060K | Other Diagnostic Substance | |
3E060KZ | Introduction of Other Diagnostic Substance into Central Artery, Open Approach | |
3E060N | Analgesics, Hypnotics, Sedatives | |
3E060NZ | Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Open Approach | |
3E060P | Platelet Inhibitor | |
3E060PZ | Introduction of Platelet Inhibitor into Central Artery, Open Approach | |
3E060R | Antiarrhythmic | |
3E060RZ | Introduction of Antiarrhythmic into Central Artery, Open Approach | |
3E060T | Destructive Agent | |
3E060TZ | Introduction of Destructive Agent into Central Artery, Open Approach | |
3E060X | Vasopressor | |
3E060XZ | Introduction of Vasopressor into Central Artery, Open Approach | |
3E060G | Other Therapeutic Substance | |
3E060GC | Introduction of Other Therapeutic Substance into Central Artery, Open Approach | |
3E060GN | Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Open Approach | |
3E060V | Hormone | |
3E060VG | Introduction of Insulin into Central Artery, Open Approach | |
3E060VH | Introduction of Human B-type Natriuretic Peptide into Central Artery, Open Approach | |
3E060VJ | Introduction of Other Hormone into Central Artery, Open Approach | |
3E060W | Immunotherapeutic | |
3E060WK | Introduction of Immunostimulator into Central Artery, Open | |
3E060WL | Introduction of Immunosuppressive into Central Artery, Open | |
3E063 | Percutaneous | |
3E0630 | Antineoplastic | |
3E06302 | Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach | |
3E06303 | Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach | |
3E06305 | Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach | |
3E0630M | Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach | |
3E0630P | Introduction of Clofarabine into Central Artery, Percutaneous Approach | |
3E0631 | Thrombolytic | |
3E06316 | Introduction of Recombinant Human-activated Protein C into Central Artery, Percutaneous | |
3E06317 | Introduction of Other Thrombolytic into Central Artery, Percutaneous Approach | |
3E0632 | Anti-infective | |
3E06328 | Introduction of Oxazolidinones into Central Artery, Percutaneous Approach | |
3E06329 | Introduction of Other Anti-infective into Central Artery, Percutaneous Approach | |
3E0633 | Anti-inflammatory | |
3E0633Z | Introduction of Anti-inflammatory into Central Artery, Percutaneous Approach | |
3E0634 | Serum, Toxoid and Vaccine | |
3E0634Z | Introduction of Serum, Toxoid and Vaccine into Central Artery, Percutaneous Approach | |
3E0636 | Nutritional Substance | |
3E0636Z | Introduction of Nutritional Substance into Central Artery, Percutaneous Approach | |
3E0637 | Electrolytic and Water Balance Substance | |
3E0637Z | Introduction of Electrolytic and Water Balance Substance into Central Artery, Percutaneous Approach | |
3E063F | Intracirculatory Anesthetic | |
3E063FZ | Introduction of Intracirculatory Anesthetic into Central Artery, Percutaneous Approach | |
3E063H | Radioactive Substance | |
3E063HZ | Introduction of Radioactive Substance into Central Artery, Percutaneous Approach | |
3E063K | Other Diagnostic Substance | |
3E063KZ | Introduction of Other Diagnostic Substance into Central Artery, Percutaneous Approach | |
3E063N | Analgesics, Hypnotics, Sedatives | |
3E063NZ | Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Percutaneous Approach | |
3E063P | Platelet Inhibitor | |
3E063PZ | Introduction of Platelet Inhibitor into Central Artery, Percutaneous Approach | |
3E063R | Antiarrhythmic | |
3E063RZ | Introduction of Antiarrhythmic into Central Artery, Percutaneous Approach | |
3E063T | Destructive Agent | |
3E063TZ | Introduction of Destructive Agent into Central Artery, Percutaneous Approach | |
3E063X | Vasopressor | |
3E063XZ | Introduction of Vasopressor into Central Artery, Percutaneous Approach | |
3E063G | Other Therapeutic Substance | |
3E063GC | Introduction of Other Therapeutic Substance into Central Artery, Percutaneous Approach | |
3E063GN | Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Percutaneous Approach | |
3E063V | Hormone | |
3E063VG | Introduction of Insulin into Central Artery, Percutaneous Approach | |
3E063VH | Introduction of Human B-type Natriuretic Peptide into Central Artery, Percutaneous Approach | |
3E063VJ | Introduction of Other Hormone into Central Artery, Percutaneous Approach | |
3E063W | Immunotherapeutic | |
3E063WK | Introduction of Immunostimulator into Central Artery, Percutaneous | |
3E063WL | Introduction of Immunosuppressive into Central Artery, Percutaneous | |
|
ICD-10-CM-2023 Code Search Engine and PCS-2023 Code Search Engine |